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Background: To describe the current treatment gap in management of cardiovascular risk factors in patients with
poorly controlled type 2 diabetes in general practice as well as the associated financial and therapeutic burden of
pharmacological treatment.
Methods: Cross-sectional analysis of data from the Patient Engagement and Coaching for Health trial. This totalled
473 patients from 59 general practices with participants eligible if they had HbA1c > 7.5%. Main outcome measures
included proportions of patients not within target risk factor levels and weighted average mean annual cost for
cardiometabolic medications and factors associated with costs. Medication costs were derived from the Australian
Pharmaceutical Benefits Schedule.
Results: Average age was 63 (range 27-89). Average HbA1c was 8.1% and average duration of diabetes was
10 years. 35% of patients had at least one micro or macrovascular complication and patients were taking a mean of
4 cardio-metabolic medications. The majority of participants on treatment for cardiovascular risk factors were not
achieving clinical targets, with 74% and 75% of patients out of target range for blood pressure and lipids
respectively. A significant proportion of those not meeting clinical targets were not on treatment at all. The
weighted mean annual cost for cardiometabolic medications was AUD$1384.20 per patient (2006-07). Independent
factors associated with cost included age, duration of diabetes, history of acute myocardial infarction, proteinuria,
increased waist circumference and depression.
Conclusions: Treatment rates for cardiovascular risk factors in patients with type 2 diabetes in our participants are
higher than those identified in earlier studies. However, rates of achieving target levels remain low despite the large
‘pill burden’ and substantial associated fiscal costs to individuals and the community. The complexities of balancing
the overall benefits of treatment intensification against potential disadvantages for patients and health care systems
in primary care warrants further investigation.
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Australia, like the rest of the world, is in the midst of an
epidemic of diabetes. Over a million Australians have
diabetes, of which over 85% is type 2 (T2DM) [1]. The
prevalence more than doubled from 1989–90 to 2004–05
and is predicted to continue rising. Diabetes and its com-
plications contributed 8.3% of the total burden of disease* Correspondence: j.furler@unimelb.edu.au
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reproduction in any medium, provided the orin Australia in 2003. It shortens life expectancy by up to
5 years and costs the community nearly $1 billion annu-
ally in direct health care costs [2], a figure that is expected
to treble over the next 40 years [3]. Future scenarios sug-
gest a progressive rise in the human and health care costs
associated with diabetes, particularly related to cardio-
vascular disease and the increasingly identified co-morbid
depression.
Evidence-based clinical care focused on treating to tar-
gets for risk factors can improve outcomes for people
with T2DM [4]. While patient-centred education andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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macotherapy is a key element of treatment for T2DM,
both for glycaemic control and associated risk factors
such as dyslipidaemia and hypertension. Targeting treat-
ment to high risk patients is felt to be important [7].
In Australia, in line with other developed countries,
there has been significant investment in programs to
improve quality of clinical care and outcomes for dia-
betes. Over the last two decades, these have included the
National Divisions Diabetes Program [8], the Australian
Primary Care Collaboratives [9], the National Integrated
Diabetes Program and targeted incentive payments to
GPs and practices [10]. The Diabetes Care Project is cur-
rently underway, to trial a system of voluntary capitation
payments to fund care for patients with diabetes in gen-
eral practice, with the aim of improving comprehensive
high quality care and reducing downstream costs (www.
dcp.org.au).
A decade ago, early in the life of these initiatives, the
gap between treatment goals and their translation into
clinical practice remained wide. An Australian study
reporting 2002 data suggested that patients with known
diabetes identified in Australian general practices had
poorly controlled disease and associated cardiovascular
risk factors [11]. That study identified 48%, 88% and
74% of patients out of target for HbA1C, cholesterol
levels and blood pressure (BP), respectively. The authors
concluded that GPs needed to be more active, particu-
larly in targeting treatment to patients with higher risk.
While targets vary from country to country, these results
are broadly comparable to those reported in the UK and
US at that time, both in published studies and in analysis
of national Quality and Outcomes Framework (QOF)
data [12,13].
We report here more recent cross-sectional data
from the Patient Engagement and Coaching for Health
(PEACH) study, a cluster randomised controlled trial of
practice nurse-led telephone coaching for patients with
poorly controlled T2DM in Australian general practices
[14]. Our primary objective is to describe the treatment
gap in management of cardiovascular risk factors, both in
the initiation, as well as the intensification, of treatment to
achieve targets. Our secondary objective is to describe the
significant ‘pill burden’ borne by patients along with
the associated financial cost and factors associated with
this cost.
Methods
The PEACH study has been described elsewhere [14].
Practices were recruited from across Victoria via mail-
outs and newsletter promotions through Divisions of
General Practice, and patients were identified from prac-
tice electronic databases or local pathology services. Pa-
tients with type 2 diabetes were eligible if their mostrecent HbA1c was within the last 12 months and was
greater than 7.5%. Patients were recruited sequentially
over 18 months through to August 2008. Baseline data for
each patient was collected within 4 weeks of recruitment.
Practice nurses (PNs) collected data via face-to-face
interviews. Height and weight were collected by the PN
according to standard instructions. BP was recorded
using usual clinical practice. The nurses also extracted
data from the patients’ medical records, including infor-
mation on complications and current medication use.
Data on medication use was based on what was pre-
scribed by the GP and was recorded in medical record
at the practice. PNs were asked to confirm drug usage
on the list and also check for any additional compli-
mentary medications taken. The PN then arranged base-
line pathology testing (HbA1c, lipids, renal function and
urinalysis). All the pathology laboratories used HbA1c
assay methods aligned with DCCT [15] and undertook
quality assurance for HbA1c and other biochemical
assays.
The PEACH study adopted target levels for risk factors
from the diabetes clinical guidelines in use in general
practice at the time [16] and from the National Heart
Foundation (Table 1).
The primary outcome of the PEACH trial was HbA1c
level at 18 months post baseline. For 80% power and 5%
significance level (two-sided test), 464 patients (8 pa-
tients per practice) from 58 primary care practices were
required (232 per group) to detect an absolute 0.5% re-
duction in mean HbA1c between the intervention and
control groups. Sample size was based on a two-sample
t-test assuming a standard deviation of 1.44 and was in-
flated by 1.3 to allow for the correlation of the patient
outcomes belonging to the same practice (assuming an
intra-cluster correlation of 0.05 and variable sample
cluster sizes) and allows for a 20% attrition rate over
18 months. A flow chart of patient recruitment is shown
in Figure 1.
The PEACH study was funded by the National Health
and Medical Research Council (NHMRC) General Prac-
tice Clinical Research Grants program. Ethics approval
was granted by the University of Melbourne Human Re-
search Ethics Committee. The trial is registered with
Current Controlled Trials (ISRCTN 50662837).
Medication cost estimation
Medications were classified into the following groups:
cardiovascular (antihypertensive, antiarrhythymic, antia-
nginal, lipid lowering, inotropic, anticoagulants and an-
tiplatelets), diabetic (oral hypoglycaemics and insulin),
antidepressants and ‘other’. Cardiometabolic medications
encompassed both cardiovascular and diabetic medica-
tions. The use of antidepressant medications was used as
a surrogate marker for the presence of depression. We
Table 1 Targets for telephone coaching
Clinical measure Target
HbA1c < 6.5%
Total cholesterol <4.0 mmol/L
LDL cholesterol <2.0 mmol/L
BP if microalbuminuria absent < 130/80
BP if microalbuminuria present < 125/75
Renal protection All patients with microalbuminuria
to be on angiotensin converting
enzyme inhibitor (ACEi) or angiotensin II
receptor blocker (ARB) unless
contraindicated
Anti-thrombotic All patients to be on anti-platelet agent
unless contraindicated
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depressant medications only.
Medication costs were based on reimbursed prices in
the Australian Pharmaceutical Benefits Schedule (PBS)
in 2006–7. These were the costs met by the Australian
Government which funds 84% of the costs of benefit-
paid pharmaceuticals in Australia, (and 52% of the costs
of all medications). They do not include co-payments by
consumers. The estimation of costs was based on the
method adopted in another Australian study [17]. In
summary, for each therapeutic class, a weighted average
daily cost was estimated by calculating the sum-product
of the cost of each drug dose and its proportional contri-
bution to the class based on the market share as listed
on the PBS. For example, assume that two drugs existed
in a class and cost $100 and $200 per year, and com-
prised 60% and 40% of the market share of the class, re-
spectively. The weighted average cost of that class would
be $100*60% + $200*40% = $140 per year. The variousFigure 1 Flowchart of participant recruitment.doses of the drug, costs and services supplied were
sourced from the PBS based on the period September
2006–Sept 2007 [18]. Where a particular drug was avail-
able in different doses, we assumed that the doses used
were those recommended in treatment guidelines [19-22].
The underlying assumption with the above method for
cost estimation is that patients were fully compliant with
their medications.
Statistical analyses
Descriptive analyses were undertaken on the baseline pa-
tient data from the PEACH study.
Statistical analyses for assessing treatment gap were
performed using SPSS for Windows version 19.0 (IBM
Corp., New York, NY). To determine proportions of
patients not within target risk factor levels, risk factor
prevalence data were cross-tabulated against data on
relevant medication use. Statistical analyses for the cost-
ing of medications were performed using PASW for Mac
version 18.0. First, a series of univariate linear regression
analyses were undertaken to identify significant factors
associated with cardiovascular and diabetes (cardio-
metabolic) medication costs. Significant variables from
these analyses were then entered into a multivariate linear
regression model to identify independent factors associ-
ated with cardio-metabolic medication costs. P values of
less than 0.05 were considered statistically significant.
Results
The baseline characteristics of participants are summa-
rised in Tables 2 (demographic) and 3 (clinical). Age
ranged from 27-89 years. 13 patients had a diabetes
duration of less than 1 year recorded. Over one third
(34%) of participants had a record in the medical file
Table 2 Demographics of participants (n = 473)
Age (years) Mean (SD) 63 (11)
Sex (%) Male 57
Smoker (%) 12
Current
Highest Level of Education (%)
Primary 22
Completed Secondary School 42
Trade or TAFE 19






Health Care Card (%) 62
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macrovascular).
The mean number of cardiometabolic medications
were 4.2 (SD 2.2) with a range of 0–13. The mean num-
ber of total medications were 7.5 (SD 4.1) with a range
of 1–24. 33.2% of participants were prescribed antide-
pressant medications at antidepressant doses. The pro-
portions of medications are shown in Table 4.Table 3 Clinical characteristics of participants
Diabetic characteristics Mean (SD)
HbA1c (%) 8.1 (1.3)
Diabetes Duration (years) 10 (7)
Systolic BP (mmHg) 138 (18)
Diastolic BP (mmHg) 79 (10)
Total Cholesterol (mmol/L) 4.5 (1.1)
Waist Circumference (cm) 109 (15)
BMI (kg/m2) 32.8 (6.5)
Medications (total) 7.5 (4.1)










Nephropathy 12.4%Table 5 shows the prevalence of cardiovascular risk
factors. Our sample had high prevalence of hypertension
and dyslipidaemia, with 74% and 75% being out of target
range for BP and lipids, respectively. Significant pro-
portions of participants with a risk factor were not onMedian Range Inter-quartile Range
7.8 5.3 – 16.0 7.3 – 8.6
10 0 – 44 5 – 14
138 90 – 221 126 – 149
80 53 – 115 72 – 85
4.4 2.5 – 12.4 3.7 – 5.0
108 68 – 167 99 – 118
31.7 19.8 – 54.5 28.1 – 36.2
7 1 – 24 5 – 10
4 0 – 13 3 – 5
Table 5 Risk factor prevalence and treatment
Risk factor Prevalence n/N (%)* Number (%) of patients with
risk factor not on treatment
BP out of target range 341/460 (74) 86 (25)
Lipids out of target range 319/424 (75) 128 (40)
Microalbuminuria or albuminuria present 122/428 (29) 35 (27) (ACEi or ARB)
Thrombotic risk present (assumed to be all participants) 473/473 (100) 250 (53) (antiplatelet)
* Risk factor prevalences have differing denominators due to some missing data.
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ticipants (73%) with albuminuria were taking angiotensin
converting enzyme inhibitors (ACEi) and/or angiotensin
receptor blockers (ARB). Lastly, only 47% of the sample
was taking anti-platelet agents.
Figures 2 and 3 illustrate the overall distribution of pa-
tients achieving target and on treatment for BP and
lipids. Among patients who were on treatment for a risk
factor, the majority remained out of target: 76% of pa-
tients on antihypertensive treatment and 70% of those
on lipid-lowering treatment.
The mean average weighed cost per year for these
medications was AUD$1384 (SD $850). Increasing age,
greater duration of diabetes, a history of acute myocar-
dial infarction (AMI), depression and the presence of
proteinuria were independent factors associated with
cardio-metabolic medication costs (Table 6).
Costs were significantly lower for patients without any
recorded diabetes complications (Table 7).
Discussion
Cardiovascular disease is the main cause of death for
people with T2DM, but with multi-factorial clinical
interventions, significant improvements in absolute car-
diovascular risk can be achieved [7]. Our primary object-
ive was to describe the treatment gap in management of
cardiovascular risk factors, both in the initiation, as well as
















Figure 2 Blood pressure (n = 460).findings identify that among patients with poorly con-
trolled T2DM in Australian general practice, the majority
are on treatment for associated cardiovascular risk factors.
We identified higher rates of treatment compared
to a decade ago in Australia [11]. This improvement
may represent the influence of guidelines and incentive
schemes and initiatives, although it may also represent
selection of a group with more severe T2DM, as our pa-
tients were selected with HbA1c above 7.5%. However,
despite the higher rates of treatment, our data shows
that substantial numbers remain untreated, contrary to
evidence-based guidelines. Our study also identified that
the majority of treated patients were not achieving tar-
gets for BP and lipids, a finding in accord with earlier
studies [11,23]. Similar findings were identified in the
UK [12] where rates of being “in-target” for BP and
cholesterol amongst patients with type 2 diabetes were
36–70% and 41–72% respectively (although targets used
in these studies were higher than those used in the
current study). Similar findings were identified in the US
[13,24].
Our secondary objective was to describe the number
of medications participants were taking together with
estimated costs associated with pharmacological treat-
ment from the perspective of the Australian government.
We found a high “pill burden” amongst our partici-
pants. While there is international population level data
about trends to increasingly intense, complex and costlyNo 
treatment














Figure 3 Lipids (n = 424).
Table 6 Weighted average mean and independent
predictors of cardiometabolic medication costs
Variable Mean cost
variance ($AU)
p value 95% CI
AMI + 1,018.45 0.000 542.88 – 1494.02
Depression + 486.45 0.000 320.73 – 652.16
Proteinuria + 215.10 0.018 36.76 – 393.44
Duration of diabetes
(+ 1 year)
+ 18.43 0.001 7.29 – 29.57
Age (+ 1 year) + 8.18 0.040 0.36 – 16.00
Waist Circumference + 7.45 0.005 2.21 – 12.69
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data published on the medication burden of individual pa-
tients. A study of 128 patients in the US [27] found they
were taking a mean of 4.1 medications to control diabetes
and an overall mean pill burden of 5.8 different medica-
tions. A study of 1,991 US primary care patients with a
HbA1c of 9.1 +/− 1.3 found they were taking a mean of
9.1 medications in total [28]. Australian data suggests that
amongst all people with diabetes less than 1% use four or
more cardiometabolic medications whereas this was the
average figure in our study [29].
Pharmaceuticals comprise one of the fastest growing
costs within the health care systems. In Australia medi-
cations for the treatment of cardiovascular disease and
diabetes are significant contributors to total PBS cost
[18]. Given the rapidly rising prevalence of T2D and
continued poor glycaemic control, the estimated mean
average weighted cost per year for cardiometabolic med-
ications of more than AUD$1384 (SD $850) per individ-
ual represents a considerable encumbrance on the PBS
system. Predictably, a history of AMI was the most sig-
nificant independent factor associated with pharmaceut-
ical cost, increasing costs by over AUD$1000 annually.
Any complication added significantly to medication costs.
Importantly, depression also independently contributed to
costs of medications, with the excess cost associated being
almost half that of AMI ($AUD486 annually). Part of the
reason for this increased cost was that patients with de-
pression used more cardio-metabolic medications (mean
5.4 vs 3.6, p <0.0001).
In the context of two decades of initiatives and incen-
tive schemes aimed at improving diabetes outcomes, is
this apparent failure on the part of GPs and patients
to embrace more intensive pharmacological treatmentTable 7 Cost of cardiometabolic medications for those
with and without complications
Complication N Mean (AUD) SD
None 307 1235.80 811.80
Any 166 1658.67 851.65
p value for difference <0.001.for T2D simply another example of clinical inertia
[28,30,31]? From a clinical perspective, this might suggest
that new strategies such as care coordinators or coaches
[32] are needed to drive further intensification of treat-
ment. After all, if patients are to be prescribed medi-
cations, they ought reasonably to expect clinical benefit
from them. Our findings may also suggest the need for
renewed effort in detecting and managing depression in
people with diabetes. We need open discussion of the cost
of such measures and the implications for sustainability of
the health system.
However, our findings may also reflect collective views
of GPs and patients about the primary aim of care for
the patient with diabetes. There is debate about the
diminishing clinical benefit and increasing personal and
lifestyle costs associated with the relentless pursuit of
surrogate markers in diabetes and cardiovascular disease
to the exclusion of hard endpoints that matter to pa-
tients [33,34]. Similar issues have been raised in relation
to the pharmacological management of depression [35].
GPs may be sensitive to this issue in their close relation-
ships with patients, aware of the burden of treatment
that patients bear and are reluctant to add to it [36].
Our findings may reflect decisions made by GPs and
their patients to limit their pursuit of biological markers
at the cost of quality of life and other patient-centred
outcomes. This may reflect an attempt by GP and patient
to say “enough is enough”, to tailor clinical decisions to the
personal context of the patient. This attention to the way
treatment can add complexity and “work” to the daily lives
and circumstances of patients living with chronic condi-
tions is an attempt to recast the issue of “non-compliance”.
Practitioners and patients in primary care may both be im-
plicitly engaging in what has been called “minimally disrup-
tive medicine” [37], balancing what is realistic and
achievable for patients against evidence based guidelines
driven by disease markers.
Understanding how patients and health practitioners
engage in this work, how they interpret evidence and
guidelines while incorporating outcomes of importance
to patients warrants much more investigation. Develop-
ment of robust measures of patient-centred outcomes to
allow their incorporation into guidelines in ways that
account for complexity, multiple morbidity and social
context, is a key area of research if evidence is to be rele-
vant to the realities of practice [38].
One important limitation of our study is selection bias.
Patients were recruited into the study on the basis of
poor glycaemic control. This may have led to a sample
of patients with poorer control of other cardiovascular
risk factors. Our results cannot be transferred to type 2
diabetes patients in general, but are only interpretable
for this selected group. Another potential limitation is
the reliability of documentation of complications in the
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determined by the PN from the medical record based on
recorded diagnoses. There may be significant variation
between practices in the documentation of individual
complication rates. We were also unable to perform qua-
lity checks on the data extraction by PNs. This may have
led to underreporting of complications. Because we as-
sumed no contraindications to treatment, the extent of
under-treatment is likely to have been over-estimated.
Our use of antidepressant medications at antidepressant
doses as a surrogate marker for depression may be an
overestimate as some patients may be on treatment for
other conditions such as anxiety. On the other hand, we
did not count those with depression but not on pharma-
cotherapy. Our costing was estimated and prices may vary
between non-concessional patients. In addition, it is very
difficult to estimate costs due to private pharmacy costs,
which can vary enormously. However, as 62% of our pa-
tients were receiving health care card benefits, our costing
was likely to have been an underestimate. Finally, the
underlying assumption underpinning annual costs was
that patients remained compliant with their medication
throughout the year. Despite its limitations, participation
of a large sample of primary care patients across Victoria
is a major strength of our study, as is the collection of de-
tailed patients’ medications data.
Conclusion
Despite significant investment of money and resources
at system and practice level, and modest improvement
in treatment rates for cardiovascular risk factors in
patients with type 2 diabetes in Australian general prac-
tice, there is still opportunity to intensify treatment to
achieve target levels. We did find evidence that greater
intensity of treatment is directed to those with higher
risk. More patients are on now treatment and for the
majority of patients, the pill burden continues to rise,
at significant cost to funders, while improved disease
markers and outcomes remain difficult to achieve. The
challenge is to understand better how practitioners and
patients balance evidence with the complex realities of
practice and to develop and include measures within
guidelines that reflect important patient priorities.
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